The paper was published in Current Opinion in Biotechnology (http://www.sciencedirect.com/science/article/pii/S0958166914001001).

‍

The paper describes the tenets of a novel metabolic engineering framework which enables a low-cost and efficient semi-combinatorial route for developing commercial strains. The core technology was founded by Professor Greg Stephanopoulos (Massachusetts Institute of Technology, MIT) and Dr. Ajikumar Parayil, Ph.D., Co-Founder and Chief Technology Officer of Manus during his time as a research fellow at MIT. “Unlike purely combinatorial approaches which require heavy investments in both library construction and screening, the multivariate modular metabolic engineering approach enables rapid strain optimization through guided semi-combinatorial library design,” says Dr. Ajikumar Parayil. “This means that it has the versatility to be rapidly deployed in a variety of hosts for a number of important pathways and systems.”